Safety Study of Inhaled 552-02 in Cystic Fibrosis Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 31, 2006

Study Completion Date

August 31, 2006

Conditions
Cystic Fibrosis
Interventions
DRUG

552-02

Trial Locations (15)

13210

State University of New York Upstate, Syracuse

15213

University of Pittsburgh, Pittsburgh

17033

Hershey Medical Center, Hershey

22908

University of Virginia, Charlottesville

27599

University of North Carolina at Chapel Hill, Chapel Hill

29425

Medical University of South Carolina, Charleston

33606

University of South Florida, Tampa

60614

Children's Memorial Hospital, Chicago

80218

The Children's Hospital, Denver

92161

University of California at San Diego, San Diego

94143-0359

University of California at San Francisco Medical Center, San Francisco

32806-1101

Nemours Children's Clinic, Orlando

68198-5190

University of Nebraska Medical Center, Omaha

07962

Morristown Memorial Hospital, Morristown

19104-4399

Children's Hospital of Philadelphia, Philadelphia

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Parion Sciences

INDUSTRY

NCT00274313 - Safety Study of Inhaled 552-02 in Cystic Fibrosis Patients | Biotech Hunter | Biotech Hunter